The five currently marketed products include morphine sulfate extended release capsules, the generic version of Kadian; fentanyl transdermal system CII, the generic equivalent of Duragesic; nifedipine extended release tablets, the generic version of Adalat CC; diltiazem hydrochloride extended release capsules, the generic equivalent of Cardizem
CD; and metoclopramide hydrochloride tablets, the generic version of Reglan.
an approval for its ANDA to market a generic version of Cardizem
CD (diltiazem HC1 extended-release capsules.
one of the first reverse settlements--or at least one of the first that attracted significant public scrutiny--involved Cardizem
CD, a brand-name prescription calcium channel blocker used to treat several heart ailments such as hypertension and angina.
Corona CA) received approval for a generic equivalent of the blood pressure drug Cardizem
16 March 2010 - US-based specialty pharmaceutical company Watson Pharmaceuticals Inc (NYSE: WPI) announced yesterday that its subsidiary Watson Laboratories has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, the generic equivalent to Biovail Laboratories International SRL's Cardizem
Q: I am taking Cardizem
and Coumadin for atrial fibrillation.
He prescribed Cardizem
to lower the patient's blood pressure, and admitted her to the Infirmary for observation in the cardiac-care unit.
In addition, if combined with Sustiva, the following drugs may require a change in the dose of either Sustiva or the other medicine: Ritadin (ritampin); Sporanox (itraconazole); Nizoral (ketoconazole); calcium-channel blockers (for example, Cardizem
, Tiazac, and others); and the cholesterol-lowering medications Lipitor (atorvastatin), Pravachol (pravastatin), and Zocor (simvastatin).
In 1998, in the In Re: Cardizem
CD Antitrust Litigation, Blue Cross Blue Shield of Wisconsin (now a subsidiary of WellPoint Inc.
LA is a once-daily calcium channel blocker.
Under the settlement, the drug manufacturers -- Aventis and Andrx -- must pay $80 million to compensate consumers, state agencies and insurance companies who overpaid for Cardizem
CD and its generic equivalents.
This lawsuit, which alleges that Aventis and Andrx unlawfully collaborated to keep a cheaper generic version of Cardizem
CD (diltiazem HCl) off the market, is without merit.